A PILOT STUDY OF THERAPY WITH PIOGLITAZONE PRIOR TO HCV TREATMENT IN HIV-1 AN

HIV-1 AN 患者在 HCV 治疗前使用吡格列酮治疗的试点研究

• 批准号: 8166569
• 负责人: RICHARD K. STERLING
• 金额: $ 0.29万
• 依托单位: VIRGINIA COMMONWEALTH UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8166569
• 关键词: Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; HIV; HIV-1; Hepatitis C; Hepatitis C virus; Institutes; Institution; Insulin Resistance; Pilot Projects; Pioglitazone; Research; Research Personnel; Resources; Retreatment; Ribavirin; Source; United States National Institutes of Health; arm; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A5239 is a single-arm, 2-step pilot study in which prior nonresponders to peginterferon (PEG-IFN) and ribavirin (RBV) therapy, with documented insulin resistance, are treated with pioglitazone prior to instituting hepatitis C retreatment. Subjects will receive 24 to 28 weeks of pioglitazone followed by continued pioglitazone therapy with PEG-IFN/RBV for up to an additional 48 weeks. Subjects will be evaluated 24 weeks after completion of hepatitis C virus (HCV) and HIV treatment to assess for sustained virologic response (SVR).

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 A5239是一项单臂，两步的试点研究，在该研究中，先前对Peginterferon（PEG-IFN）和利巴韦林（RBV）治疗，并具有记录的胰岛素抵抗，并在对肝炎恢复之前用吡格列唑酮进行治疗。受试者将接受24至28周的吡格列酮，然后再进行PIG-IFN/RBV持续的吡格列酮治疗，多达48周。丙型肝炎病毒（HCV）和HIV治疗完成后24周将评估受试者，以评估持续的病毒学反应（SVR）。